Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
MaxCyte ( (MXCT) ) just unveiled an update.
MaxCyte, Inc. and Ori Biotech have announced a strategic collaboration to enhance the efficiency and scalability of cell therapy manufacturing. By integrating MaxCyte’s ExPERT™ platform with Ori’s IRO® platform, the partnership aims to improve the yield of gene-edited T cells and streamline manufacturing timelines, ultimately accelerating the availability of transformative treatments for patients. This collaboration highlights the companies’ commitment to innovation and industry collaboration, providing therapy developers with integrated solutions to make next-generation treatments more accessible globally.
More about MaxCyte
MaxCyte, Inc. is a leading cell-engineering company focused on advancing the discovery, development, and commercialization of next-generation cell therapeutics. The company provides platform technologies that enable precise, efficient, and scalable cell engineering, supporting researchers globally in developing safe and effective treatments. Ori Biotech is a manufacturing technology company based in London and Philadelphia, dedicated to enabling widespread patient access to life-saving cell and gene therapies through its next-generation manufacturing platform, IRO®.
Find detailed analytics on MXCT stock on TipRanks’ Stock Analysis page.